(Sacubitril + valsartan) is a Small Molecule owned by Novartis, and is involved in 85 clinical trials, of which 68 were completed, 14 are ongoing, and 3 are planned.
Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Sacubitril is an inhibitor of neutral endopeptidase inhibitor. NEP is an enzyme responsible for the breakdown of natriuretic peptides that can help to counteract many the physiologic and structural changes associated with heart failure.
The revenue for (Sacubitril + valsartan) is expected to reach a total of $943m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Sacubitril + valsartan) NPV Report.
(Sacubitril + valsartan) Overview
Sacubitril and Valsartan (Entresto, Neparvis, Uperio, Azmarda, LCZ696, Vymada) is a fixed dose combination acts as an anti hypertensive and cardiovascular agent. It is formulated as film coated tablets for oral route of administration. Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction. Entresto also indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. Entresto is indicated for the treatment of hypertension. LCZ696 is a single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug sacubitril. Entresto is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular death and heart failure hospitalization. LCZ-696 is under development for the treatment of non-obstructive hypertrophic cardiomyopathy, post-acute myocardial infarction and chronic heart failure with preserved and reduced ejection fraction (diastolic heart failure) (HF-PEF), left ventricular dysfunction and pediatric heart failure due to systemic left ventricle systolic dysfunction. It was also under development for the treatment of essential hypertension and systolic hypertension.
Laboratorios Farmaceuticos Rovi Overview
Laboratorios Farmaceuticos Rovi (Rovi) is a pharmaceutical company that carries out the research, development, manufacturing, and marketing of prescription and hospital products. The company’s product portfolio includes licensed prescription pharmaceuticals in the therapeutic areas of cardiovascular, osteoarticular, thrombosis, pneumology, gynecology, central nervous system (CNS), endocrinology, oncology, and urology; diagnostic imaging products include contrast agents and injection systems for imaging procedures such as computed tomography, X-rays, magnetic resonance imaging and ultrasound screening; products for the care and maintenance of venous and arterial catheters. The company markets its products in Italy, the UK, Austria, Ireland, Hungary, Poland, Spain, Portugal and others. Rovi is headquartered in Madrid, Spain.
The company reported revenues of (Euro) EUR648.7 million for the fiscal year ended December 2021 (FY2021), an increase of 54.5% over FY2020. In FY2021, the company’s operating margin was 28%, compared to an operating margin of 17.8% in FY2020. In FY2021, the company recorded a net margin of 23.6%, compared to a net margin of 14.5% in FY2020. The company reported revenues of EUR195.1 million for the third quarter ended September 2022, a decrease of 48.7% over the previous quarter.
Quick View – (Sacubitril + valsartan)
|Highest Development Stage|